Royalty Pharma plc
RPRX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001802768
In the last 90 days, Royalty Pharma plc insiders filed 0 open-market purchases and 5 sales; 651 institutions reported holding it in 13F filings for Q2 2026, worth $20.6B in total; Dorsey Asset Management is the only superinvestor holding it.
Key figures
- Market capNo recent share count in SEC filings
- –
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $13.0M in total
- 5
- 13F holdersQ2 2026, +63 vs. previous quarter
- 651
- 13F valueReported value at the end of Q2 2026
- $20.6B
- Superinvestors holdingAt the end of Q2 2026
- 1
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $2.38B
- +5.1% year over year
- Net income, FY2025
- $770.9M
- −10.2% year over year
- Free cash flow, FY2025
- –
- No comparable prior period
- Revenue, Q3 FY2026
- $690.1M
- +13.3% year over year
Short interest
See short dataFrom FINRA, settlement date Oct 15, 2026.
- Short interest
- 12.8M
- Shares sold short
- Change
- −42.0K
- −0.3% vs. previous
- Days to cover
- 4.28
- At average daily volume
Superinvestors holding RPRX, Q2 2026
Go to the superinvestors tab1 superinvestor reports holding Royalty Pharma plc on Form 13F. Percentages are the stock's share of each portfolio.
Dorsey Asset Management
Pat Dorsey
8.8%
Royalty Pharma plc's share of the portfolio
- Shares
- 2,456,528
- Value
- $137.7M
Latest insider trades
See all insider tradesOpen-market purchases and sales by Royalty Pharma plc insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 5, 2026 (view filing)5:12 PM ET | Oct 5 | Same day | Urist MarshallEVP, Research & Investments | SSaleClass A Ordinary Shares | −4.13K | $57.10 | −$235.6K | −100.0%0 after | 10b5-1 |
| Sep 30, 2026 (view filing)4:32 PM ET | Sep 28 | 2 days | Urist MarshallEVP, Research & Investments | SSaleClass A Ordinary Shares | −4.13K | $57.88 | −$238.8K | −50.0%4.13K after | 10b5-1 |
| Sep 24, 2026 (view filing)4:10 PM ET | Sep 22 | 2 days | Hite ChristopherEVP & Chairman, Partnering | SSaleClass A Ordinary Shares | −100.0K | $58.53 | −$5.85M | −27.0%270.4K after | 2 lots10b5-1 |
| Aug 19, 2026 (view filing)4:20 PM ET | Aug 18 | 1 day | Hite ChristopherEVP & Chairman, Partnering | SSaleClass A Ordinary Shares | −100.0K | $59.97 | −$6.00M | −21.3%370.4K after | 10b5-1 |
| Aug 17, 2026 (view filing)5:01 PM ET | Aug 13 | 4 days | Coyne Terrance P.EVP & CFO | SSaleClass A Ordinary Shares | −11.0K | $58.68 | −$645.6K | −100.0%0 after | 2 lots10b5-1 |
| Jul 2, 2026 (view filing)4:10 PM ET | Jul 1 | 1 day | Urist MarshallEVP, Research & Investments | SSaleClass A Ordinary Shares | −9.10K | $55.88 | −$508.5K | −100.0%0 after | 10b5-1 |
| Jul 2, 2026 (view filing)4:08 PM ET | Jun 30 | 2 days | Hite ChristopherEVP & Chairman, Partnering | SSaleClass A Ordinary Shares | −100.0K | $56.52 | −$5.65M | −17.9%459.4K after | 2 lots10b5-1 |
| Jul 2, 2026 (view filing)4:08 PM ET | Jun 30 | 2 days | Hite ChristopherEVP & Chairman, Partnering | SSaleClass A Ordinary Shares | −30.0K | $56.46 | −$1.69M | −42.9%40.0K after | 2 lots10b5-1 |
| Jun 25, 2026 (view filing) | Jun 24 | 1 day | Urist MarshallEVP, Research & Investments | SSaleClass A Ordinary Shares | −9.10K | $55.18 | −$502.0K | −50.0%9.10K after | 10b5-1 |
| Jun 25, 2026 (view filing) | Jun 23 | 2 days | Hite ChristopherEVP & Chairman, Partnering | SSaleClass A Ordinary Shares | −150.0K | $54.39 | −$8.16M | −21.1%559.4K after | 2 lots10b5-1 |
Top 10 13F holders, Q2 2026
See all 651 holdersThe largest institutional positions in Royalty Pharma plc at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Morgan Stanley | 42,931,597 | $2.41B | 0.13% | −640,036−1.5% | Reduced |
| Capital International Investors | 35,273,770 | $1.98B | 0.41% | +268,034+0.8% | Added |
| BlackRock, Inc. | 27,832,977 | $1.56B | 0.02% | +1,925,232+7.4% | Added |
| FMR LLC | 24,513,814 | $1.37B | 0.06% | −638,428−2.5% | Reduced |
| State Street Corp | 12,338,229 | $691.8M | 0.02% | +1,348,378+12.3% | Added |
| Price T Rowe Associates Inc | 11,193,657 | $627.6M | 0.06% | +9,259,396+478.7% | Added |
| Swedbank AB | 10,726,608 | $601.4M | 0.52% | −860,085−7.4% | Reduced |
| Baillie Gifford & Co | 10,015,578 | $561.6M | 0.51% | −6,140,099−38.0% | Reduced |
| Capital World Investors | 9,517,337 | $533.6M | 0.06% | +1,480,623+18.4% | Added |
| Geode Capital Management, LLC | 8,058,048 | $450.6M | 0.02% | +188,416+2.4% | Added |
Holders of 5% or more of RPRX
See all 4 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Royalty Pharma plc.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Legorreta Pablo G. | 13D/A | 18.73%101.8M shares | −1.01 ppfrom 19.74% | May 23, 20252 filings | Aug 17, 2026 | SEC |
| Morgan Stanley | 13G/A | 9.20%38.9M shares | – | Feb 9, 20217 filings | Aug 5, 2025 | SEC |
| Capital International Investors | 13G/A | 8.80%37.8M shares | +1.10 ppfrom 7.70% | Aug 13, 20254 filings | May 14, 2026 | SEC |
| BlackRock, Inc. | 13G | 5.70%25.4M shares | New | Feb 4, 20251 filing | Feb 4, 2025 | SEC |